Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 10/20 | 0.57 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501301 | 1.00 | PANK3 (0.57) | PANK3ADAMTS5CHRM1SMOTLR9 | |
| SCHEMBL21424138 | 0.90 | PANK3 (0.72) | PANK3ADAMTS5 | |
| SCHEMBL21424139 | 0.90 | PANK3 (0.72) | PANK3ADAMTS5 | |
| SCHEMBL31717684 | 0.90 | PANK3 (0.72) | PANK3ADAMTS5 | |
| SCHEMBL31717579 | 0.90 | PANK3 (0.72) | PANK3ADAMTS5 | |
| SCHEMBL19748422 | 0.87 | PANK3 (0.74) | PANK3 | |
| SCHEMBL21406210 | 0.87 | PANK3 (0.74) | PANK3 | |
| SCHEMBL31717871 | 0.87 | PANK3 (0.74) | PANK3 | |
| SCHEMBL19748421 | 0.87 | PANK3 (0.74) | PANK3 | |
| SCHEMBL31717891 | 0.87 | PANK3 (0.74) | PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885ADAMTS5 3055/4885CHRM1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.